Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report
Conclusions:
Twenty-four weeks of acarbose monotherapy in newly diagnosed patients with T2D is associated with significantly increased levels of both fasting and postprandial GLP-1 as well as significantly increased NO levels and NOS activity for those patients in whom postprandial GLP-1 levels were increased. Therefore, the benefits of acarbose on cardiovascular risk may be related to its stimulation of GLP-1 secretion.
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Miao-yan ZhengJu-hong YangChun-yan ShanHong-tao ZhouYan-guang XuYing WangHui-zhu RenBao-cheng ChangLi-ming Chen Source Type: research
More News: Acarbose | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart